Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron) for ...

December 23, 2024

FDA approves GEMTESA® (vibegron), a β3 agonist, for men with OAB symptoms on BPH therapy, marking it the first and only such treatment available in the U.S.

Highlighted Terms

overactive bladder vibegron benign prostatic hyperplasia U.S. Food and Drug Administration Sumitomo Pharma America GEMTESA

Related News

prnewswire.com

Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron) for ...

FDA approves GEMTESA® (vibegron), a β3 agonist, for men with OAB symptoms on BPH therapy, marking it the first and only such treatment available in the U.S.